Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antifibrinolytic agent |
| gptkbp:administeredBy |
orthopedic surgery
cardiac surgery liver surgery menorrhagia prostate surgery postpartum hemorrhage epistaxis (nosebleeds) dental procedures in hemophilia melasma (off-label) trauma-related bleeding |
| gptkbp:ATCCode |
B02AA02
|
| gptkbp:brand |
Cyklokapron
Lysteda |
| gptkbp:CASNumber |
1197-18-8
|
| gptkbp:category |
hemostatic agent
lysine analogue |
| gptkbp:chemicalFormula |
C8H15NO2
|
| gptkbp:contraindication |
history of thrombosis
active intravascular clotting |
| gptkbp:discoveredBy |
Utako Okamoto
|
| gptkbp:discoveredIn |
1962
|
| gptkbp:eliminationHalfLife |
2 hours
|
| gptkbp:excretion |
renal
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tranexamic acid
|
| gptkbp:interactsWith |
oral contraceptives
factor IX complex concentrates tretinoin (topical) |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits activation of plasminogen to plasmin
|
| gptkbp:meltingPoint |
300°C
|
| gptkbp:metabolism |
minimal
|
| gptkbp:molecularWeight |
157.21 g/mol
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:riskFactor |
increased risk of thrombosis
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
nausea
vomiting diarrhea visual disturbances |
| gptkbp:synonym |
trans-4-(aminomethyl)cyclohexanecarboxylic acid
|
| gptkbp:usedFor |
treatment of heavy menstrual bleeding
treatment of hereditary angioedema prevention of excessive bleeding during surgery |
| gptkbp:WHOModelListOfEssentialMedicines |
true
|
| gptkbp:bfsParent |
gptkb:Thrombolytics
|
| gptkbp:bfsLayer |
7
|